新相微：2025年前三季度净利润约818万元

Group 1 - New Xiangwei (SH 688593) reported Q3 performance with revenue of approximately 436 million yuan, a year-on-year increase of 27.21% [1] - The net profit attributable to shareholders was approximately 8.18 million yuan, reflecting a year-on-year increase of 138.88% [1] - Basic earnings per share reached 0.018 yuan, up 125% year-on-year [1] Group 2 - As of the report, New Xiangwei's market capitalization stands at 10.2 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion USD this year [2] - There is a contrast in the biopharmaceutical secondary market's heat versus the cooling fundraising in the primary market [2]